CYP2C19基因型对症状性冠心病、卒中和外周动脉疾病患者临床结局的影响:系统评价与荟萃分析
在冠心病中基因型指导治疗显著降低MACE、心肌梗死和支架血栓风险,且不增加大出血;卒中患者中LOF携带者MACE和复发性卒中风险显著升高;PAD证据有限。
要点
- 冠心病患者基因型指导治疗较标准抗栓显著降低MACE(RR 0.60,95%CI 0.43-0.83)。
- 卒中患者中CYP2C19 LOF携带者MACE风险显著升高(RR 1.61,95%CI 1.25-2.08)。
- PAD患者中主要肢体不良事件证据有限,尚无法得出有意义结论。
核心结论
- 基因型指导治疗显著降低冠心病患者动脉粥样硬化血栓事件率,尤其是PCI术后。
- 有卒中史的患者中,携带CYP2C19 LOF等位基因并接受氯吡格雷治疗者MACE和复发性卒中风险更高。
- PAD患者中关于主要肢体不良事件的现有证据过于有限,无法得出有意义的结论。
研究设计与样本
- 系统检索PubMed、EMBASE和MEDLINE从建库至2023年7月23日的文献。
- 纳入比较基因型指导与标准抗栓治疗的随机对照试验,以及关于氯吡格雷治疗患者CYP2C19基因型与临床结局关联的队列研究和RCT事后分析。
- 主要疗效终点为MACE,安全性终点为大出血;次要终点包括心肌梗死、支架血栓和缺血性卒中。
- PROSPERO注册号CRD42020220284。
主要发现
- 冠心病中,基因型指导治疗较标准抗栓显著降低MACE(RR 0.60,95%CI 0.43-0.83)、心肌梗死(RR 0.53,95%CI 0.42-0.68)和支架血栓(RR 0.64,95%CI 0.43-0.94)。
- 冠心病中,基因型指导治疗与标准抗栓的大出血率无显著差异(RR 0.93,95%CI 0.70-1.23)。
- 大多数RCT在经皮冠状动脉介入治疗(PCI)术后患者中进行(9/11)。
- 卒中中,LOF携带者较非携带者MACE风险显著升高(RR 1.61,95%CI 1.25-2.08),复发性缺血性卒中风险显著升高(RR 1.89,95%CI 1.48-2.40)。
- 卒中中,LOF携带者与非携带者的大出血无显著差异(RR 0.90,95%CI 0.43-1.89)。
关键数值与推荐
- 冠心病:基因型指导治疗较标准抗栓降低MACE(RR 0.60,95%CI 0.43-0.83)、心肌梗死(RR 0.53,95%CI 0.42-0.68)、支架血栓(RR 0.64,95%CI 0.43-0.94),大出血无显著差异(RR 0.93,95%CI 0.70-1.23)。
- 卒中:LOF携带者较非携带者MACE风险升高(RR 1.61,95%CI 1.25-2.08),复发性缺血性卒中风险升高(RR 1.89,95%CI 1.48-2.40),大出血无显著差异(RR 0.90,95%CI 0.43-1.89)。
- PAD:EUCLID试验6955例接受氯吡格雷治疗的症状性PAD患者中,LOF携带者与非携带者MACE或大出血无差异。
临床怎么用
- 冠心病患者,尤其是PCI术后,可依据CYP2C19基因型指导抗栓治疗以降低MACE、心肌梗死和支架血栓风险。
- 有卒中史且携带CYP2C19 LOF等位基因者接受氯吡格雷治疗时MACE和复发性卒中风险较高,需考虑替代抗栓策略。
- PAD患者中CYP2C19基因型指导治疗的证据尚不充分,临床决策需个体化。
局限性
- PAD患者中关于主要肢体不良事件的现有证据过于有限,无法得出有意义的结论。
- 大多数RCT在PCI术后患者中进行(9/11),冠心病其他人群的证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clopidogrel is widely used for the secondary prevention of atherothrombotic events in patients with coronary artery disease (CAD), ischemic stroke, and peripheral arterial disease (PAD). CYP2C19 plays a pivotal role in the conversion of clopidogrel to its active metabolite. Clopidogrel-treated carriers of a CYP2C19 loss-of-function allele (LOF) may have a higher risk of new atherothrombotic events. Previous studies on genotype-guided treatment were mainly performed in CAD and showed mixed results. PURPOSE: To simultaneously investigate the impact of CYP2C19 genotype status on the rate of atherothrombotic events in the most common types of atherosclerotic disease (CAD, stroke, PAD). METHODS: A comprehensive search in Pubmed, EMBASE, and MEDLINE from their inception to July 23rd 2023 was performed. Randomized controlled trials (RCTs) comparing genotype-guided and standard antithrombotic treatment, and cohort studies and post hoc analyses of RCTs concerning the association between CYP2C19 genotype status and clinical outcomes in clopidogrel-treated patients were included. The primary efficacy endpoint was major adverse cardiovascular events (MACE) and the safety end point major bleeding. Secondary endpoints were myocardial infarction, stent thrombosis, and ischemic stroke. RESULTS: Forty-four studies were identified: 11 studies on CAD, 29 studies on stroke, and 4 studies on PAD. In CAD, genotype-guided therapy significantly reduced the risk of MACE [risk ratio (RR) 0.60, 95% confidence interval (CI) 0.43-0.83], myocardial infarction (RR 0.53, 95% CI 0.42-0.68), and stent thrombosis (RR 0.64, 95% CI 0.43-0.94), compared with standard antithrombotic treatment. The rate of major bleeding did not differ significantly (RR 0.93, 95% CI 0.70-1.23). Most RCTs were performed in patients after percutaneous coronary intervention (9/11). In stroke, LOF carriers had a significantly higher risk of MACE (RR 1.61, 95% CI 1.25-2.08) and recurrent ischemic stroke (RR 1.89, 95% CI 1.48-2.40) compared with non-carriers. No significant differences were found in major bleeding (RR 0.90, 95% CI 0.43-1.89). In the 6955 patients with symptomatic PAD treated with clopidogrel in the EUCLID trial, no differences in MACE or major bleeding were found between LOF carriers and non-carriers. In three smaller studies on patients with PAD treated with clopidogrel after endovascular therapy, CYP2C19 genotype status was significantly associated with atherothrombotic events. CONCLUSIONS: Genotype-guided treatment significantly decreased the rate of atherothrombotic events in patients with CAD, especially after PCI. In patients with history of stroke, LOF carriers treated with clopidogrel had a higher risk of MACE and recurrent stroke. The available evidence in PAD with regard to major adverse limb events is too limited to draw meaningful conclusions. REGISTRATION: PROSPERO identifier no. CRD42020220284.
引用
- Maas DPMSM, Willems LH, Kranendonk J, et al. Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Drugs. 2024. PMID: 39235670. doi:10.1007/s40265-024-02076-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。